Overview: Angelman Syndrome TestIntroduction: The Angelman Syndrome Test detects genetic changes causing Angelman syndrome, a disorder leading to developmental delays, seizures, or speech problems. Aligned with 2023 ACMG guidelines, it uses PCR for high specificity, aiding in genetic screening. This test is critical for guiding diagnosis, management, and improving outcomes in molecular pathology for patients with suspected neurodevelopmental disorders.
Other Names: Angelman Syndrome Genetic Assay, UBE3A Mutation Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Angelman syndrome genetics were identified in the 1980s. PCR-based testing emerged in the 1990s, and by the 2000s, advanced sequencing improved detection of UBE3A mutations.
Purpose: Diagnoses Angelman syndrome, guides management, and monitors genetic risk in patients with developmental delays, seizures, or speech problems.
Test Parameters: 1. Angelman Syndrome Gene Mutation
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva at any time. Report symptoms like developmental delays or seizures, and list medications like anticonvulsants.
Specimen: 2-5 mL whole blood (EDTA), 1-2 buccal swabs (sterile swab), or 1-2 mL saliva (sterile container). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document neurodevelopmental symptoms, family history of genetic disorders, or seizure history. Include current medications, especially anticonvulsants.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for genetic counseling.
Procedural Considerations: Uses PCR to detect UBE3A mutations or methylation defects. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Improper storage or delayed transport can degrade nucleic acids. Contamination or low sample quality may affect PCR sensitivity.
Clinical Significance: Detection of UBE3A mutations confirms Angelman syndrome, prompting supportive therapies or genetic counseling. Negative results may require additional genetic testing.
Specialist Consultation: Consult a geneticist or neurologist for result interpretation. Genetic counseling is advised for affected families.
Additional Supporting Tests: Methylation analysis, FISH, or whole-exome sequencing to confirm Angelman syndrome or rule out related disorders.
Test Limitations: Rare mutations may be missed. Results require clinical correlation with phenotypic features.
References: ACMG Angelman Syndrome Guidelines, 2023; Genetics in Medicine, Dagli AI, 2022.
